Pharmacokinetics of Dapsone Gel, 5% for the Treatment of Acne Vulgaris
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Oral dapsone has been available for over 60 years and has been used to treat severe acne vulgaris; however, the oral formulation is known to cause dose-dependent haematological reactions and is currently indicated only for diseases such as dermatitis herpetiformis and Hansen’s disease. A gel formulation of dapsone was recently developed to treat acne vulgaris. As dapsone is administered topically, it was expected that systemic absorption would be considerably lower than that observed with oral dapsone therapy, thereby avoiding any adverse haematological effects.
To report the pharmacokinetic profile of topically applied dapsone gel, 5% in the treatment of acne vulgaris.
Study participants and methods
Three prospective, open-label studies enrolled a total of 548 subjects with acne vulgaris: two phase I pharmacokinetic studies (crossover and drug interaction) and one phase III long-term safety study. In the crossover study (n = 18), topical dapsone gel applied twice daily for a total of 14 days to 22.5% of the body surface area was compared with a single dose of oral dapsone 100mg (the typical clinical dose). In the drug-interaction study (n = 24), oral trimethoprim/sulfamethoxazole monotherapy, topical dapsone gel monotherapy and the two in combination were used twice daily for 7, 21 and 7 days, respectively. In the long-term safety study (n = 506), topical dapsone gel was applied twice daily to acne-affected areas for up to 12 months. Blood samples were drawn at various timepoints in each study to assess drug and metabolite concentrations. Systemic concentrations of dapsone, N-acetyl dapsone, dapsone hydroxylamine, trimethoprim and sulfamethoxazole were determined, according to the study design.
In the crossover study, the mean area under the plasma concentration-time curve (AUC) from 0 to 24 hours for dapsone was 417.5 ng · h/mL after 2 weeks of dapsone gel therapy (n = 10), compared with an AUC from time zero to infinity of 52 641 ng · h/mL after a single dose of oral dapsone; this represents a 126-fold lower systemic exposure for dapsone gel at typical therapeutic doses. In the drug-interaction study, the AUC from 0 to 12 hours for dapsone was 221.52 ng · h/mL after 3 weeks of dapsone gel monotherapy compared with 320.3 ng · h/mL after 1 week of coadministration with trimethoprim/sulfamethoxazole. In the long-term safety study, the mean plasma dapsone concentrations ranged from 7.5 to 11 ng/mL over 12 months. Overall, total systemic exposures to dapsone and its metabolites were approximately 100-fold less for dapsone gel than for oral dapsone, even in the presence of trimethoprim/ sulfamethoxazole. There were no reports of any haematological adverse events.
Topical application of dapsone gel in various settings ranging from 2 weeks to 12 months resulted in systemic exposures to dapsone and its metabolites that were approximately 100-fold less than those after oral dapsone at a therapeutic dose level. The concentrations of dapsone and its metabolites reached steady state and did not increase during prolonged treatment.
- Stern RS. Dermatologists and office-based care of dermatologic disease in the 21st century. J Invest Dermatol Symp Proc 2004; 9: 126–30 CrossRef
- Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004; 292: 726–35 CrossRef
- Harper JC, Thiboutot DM. Pathogenesis of acne: recent research advances. Adv Dermatol 2003; 19: 1–10
- Cunliffe WJ, Holland DB, Clark SM, et al. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol 2000; 142: 1084–91 CrossRef
- Jeremy AHT, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121: 20–7 CrossRef
- Jappe U. Pathological mechanisms of acne with special emphasis on Propionibacterium acnes and related therapy. Acta Derm Venereol 2003; 83: 241–8 CrossRef
- Pawin H, Beylot C, Chivot M, et al. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol 2004; 14: 4–12
- Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin 2001; 19: 79–86 CrossRef
- Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001; 45: 420–34 CrossRef
- Jacobus Pharmaceutical Co., Inc. Dapsone prescribing information. Princeton (NJ): Jacobus Pharmaceutical Co., Inc, 1997
- Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol 1961; 73: 367–70 CrossRef
- Prendiville JS, Logan RA, Russell-Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Clin Exp Dermatol 1988; 13: 67–71 CrossRef
- Wolf R, Matz H, Orion E, et al. Dapsone. Dermatol Online J 2002; 8: 2
- Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007 Mar; 56(3): 439.e1–439.e10 CrossRef
- Roberts J, Maloney M, Ling M, et al. 5% dapsone topical gel: safety and efficacy with long-term (1 year) treatment for acne vulgaris [abstract]. J Am Acad Dermatol 2005; 52 Suppl.: P5
- US FDA Center for Drug Evaluation and Research. Guidance for industry: in vivo drug metabolism/drug interaction studies -study design, data analysis, and recommendations for dosing and labelling. Rockville (MD): Center for Drug Evaluation and Research, 1999 [online]. Available from URL: http://www.fda.gov/cber/gdlns/metabol.pdf [Accessed 2007 June 28]
- Zuidema J, Hilbers-Moderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986; 11: 299–315 CrossRef
- Mitra AK, Thummel KE, Kalhorn TF, et al. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 1995; 58: 556–66 CrossRef
- Pharmacokinetics of Dapsone Gel, 5% for the Treatment of Acne Vulgaris
Volume 46, Issue 8 , pp 697-712
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
- 2. Cantest Clinical Research Ltd, Vancouver, British Columbia, Canada
- 3. Madison Skin and Research, Inc., Madison, Wisconsin, USA
- 4. Howard University College of Medicine, Washington, District of Columbia, USA
- 5. QLT USA, Inc., Fort Collins, Colorado, USA